home / stock / skye / skye news

SKYE News and Press, Skye Bioscience Inc Com From 04/19/21

Stock Information
Company Name: Skye Bioscience Inc Com
Stock Symbol: SKYE
Market: NASDAQ
Website: skyebioscience.com
Menu
SKYE SKYE Quote SKYE Short SKYE News SKYE Articles SKYE Message Board
Get SKYE Alerts

News, Short Squeeze, Breakout and More Instantly...
SKYE - Keynotes, Educational Panels and 66 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on April 20-22, 2021

LOS ANGELES, CA / ACCESSWIRE / April 19, 2021 / The Planet MicroCap Showcase will take place on April 20-22, 2021, where 66 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience. The Planet MicroCap Showcase: VIRTU...
SKYE - Skye Bioscience to Present at Upcoming Investment Conferences in April

San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant u...

SKYE - Skye Bioscience to Present at Benzinga Biotech Small Cap Conference

San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant ...

SKYE - Skye Bioscience posts preclinical data from eye disease treatment study

Skye Bioscience (SKYE) announces preclinical data showing that THCVHS, the company’s novel THC prodrug, showed no signs of irritation of the eye using an in vitro assay, the EpiOcular  MTT ET-50.The EpiOcular  MTT ET-50 risk assessment assay determines the...
SKYE - Skye Bioscience's Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment

San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant ...

SKYE - Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board

San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with s...

SKYE - Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference

San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with s...
SKYE - Cannabis Legalization In Mexico; Here Is A List Of Companies Poised To Benefit

Mexico with 121 million citizens will likely legalize cannabis by April of this year opening the door to the largest population for potential customers; This will be a game-changing tipping point for legalization of cannabis around the world and especially throughout Latin America; ...

SKYE - Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing

Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations PR Newswire NEW YORK , Feb. 8, 2021 ...

SKYE - Skye Bioscience to Participate in Investment Conferences in February

San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with si...
Previous 10 Next 10